Result of EGM

RNS Number : 1495P

Uniphar PLC

15 February 2021

 

Results of EGM

Dublin, London | 15 February 2021

Uniphar plc is pleased to announce that at the Extraordinary General Meeting held at 11.00 a.m. today, 15 February 2021, each of the resolutions set out in the Notice of Extraordinary General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie , were duly passed without amendment.

These resolutions relate to the replacement of CREST with Euroclear Bank for electronic settlement of trading in the ordinary shares of the Company.

--- ENDS ---

For further details contact:

Uniphar	[phone]
Brian O'Shaughnessy
Group Director of Corporate Development	[e-mail]
Davy	[phone]
(Joint Corporate Broker, Nominated Adviser and Euronext Growth Adviser)
Fergal Meegan
Barry Murphy
Orla Cowzer
RBC Capital Markets (Joint Corporate Broker)	[phone]
Darrell Uden
Jonathan Hardy
Jamil Miah
Stifel Nicolaus Europe Limited (Joint Corporate Broker)	[phone]
Matt Blawat
Ben Madison
Francis North
Q4 PR	[phone] or
(Public Relations Adviser to Uniphar)	[phone]
Iarla Mongey

About Uniphar plc  

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business, servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail.

The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With more than 2,500 colleagues, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US, delivering unlicensed and specialty medicine on a global basis.

The Group's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux, and the Nordics, the Group is growing with its clients to provide pan-European solutions. Uniphar has built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market share in the wholesale/hospital market, supported by a network of c.335 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are utilised for the benefit of the growth divisions, Commercial & Clinical and Product Access.

 

END

 

 

ROMFLFFSFLIELIL